March 14, 2019 10:09 AM EDTUpdated 10:53 AM

Bristol-Myers dodges a bullet as PTAB turns down inter partes review pitch for Celgene's cash cow

John Carroll

Editor & Founder

Celgene just won another crucial patent skirmish in its ongoing fight to keep its blockbuster revenue pumping in from Revlimid — a key feature in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Bristol-Myers dodges a bullet as PTAB turns down inter partes review pitch for Celgene's cash cow

John Carroll

Editor & Founder

Sign up to read this article for free.

Lack of detail in Trump's drug price plan raises more questions than answers

Updated: White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Roche could rethink $50B US expansion plan if new policies 'harm' operations

Pharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise

Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

PBM overhaul and drug price negotiations make the cut in Republicans' tax bill

Bris­tol-My­ers dodges a bul­let as PT­AB turns down in­ter partes re­view pitch for Cel­gene's cash cow

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

Bristol-Myers dodges a bullet as PTAB turns down inter partes review pitch for Celgene's cash cow

Lack of detail in Trump's drug price plan raises more questions than answers

Updated: White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Roche could rethink $50B US expansion plan if new policies 'harm' operations

Pharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise

Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology

PBM overhaul and drug price negotiations make the cut in Republicans' tax bill